Industry watchers looking for a clear answer on the fate of the market for patent foramen ovale closure as a stroke treatment at this year’s Transcatheter Cardiovascular Therapeutics annual conference were likely disappointed.
The results from two hotly anticipated studies evaluating St. Jude Medical Inc.’s Amplatzer PFO occluder for patent foramen ovale closure sparked a range of interpretations from practitioners at the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?